Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study

Zanetti, Alessandro; Mariano, Andrea; Romanò, Luisa; D’Amelio, Raffaele; Chironna, Maria; Coppola, Rosa; Cuccia, Mario; Mangione, Rossana; Marrone, Fosca; Negrone, Francesco Saverio; Parlato, Antonino; Zamparo, E.; Zotti, Carla Maria; Stroffolini, Tommaso; Mele, Alfonso

doi:10.1016/s0140-6736(05)67568-x

Cited by 323 publications

(247 citation statements)

References 27 publications

Supporting

Mentioning

215

Contrasting

Unclassified

Order By: Relevance

“…Also, there are authors who suggest that strong immunologic memory persists for more than 10 years once the complete vaccination scheme has been administered properly and therefore, an anamnestic anti-HBs response is achieved after HBV contact, even if anti-HBs titers are not higher than 10IU/L 29,30,31,32,33 . Thus, considering that our volunteers were vaccinated approximately 10 years ago, and that anti-HBs titers wane through the years even though immunologic memory persists, we can consider that the present research found that in Chapecó, there is a vaccine coverage of 87.6% (which corresponds to all subjects with detectable anti-HBs titers).…”

Section: Resultsmentioning

confidence: 99%

Seroprevalence of hepatitis B and hepatitis C markers in adolescents in Southern Brazil

et al. 2011

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Seroprevalence of hepatitis B and hepatitis C markers in adolescents in Southern Brazil

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Primary vaccination with a three-dose series of hepatitis B vaccine results in seroprotection: defined as the development of anti-HBs at a concentration greater than 10 mille International Units per milliliter [mIU/mL]) in > 95% of vaccinated infants and children 29 . However, following completion of the primary series, anti-HBs concentrations decline and can fall below 10mIU/mL after several years [30][31][32][33] .…”

Section: Ethical Considerationsmentioning

confidence: 99%

Hepatitis B marker seroprevalence and vaccination coverage in adolescents in the City of Itajaí, State of Santa Catarina, Southern Brazil, in 2008

Tonial

Passos

Livramento

et al. 2011

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

Introduction: Hepatitis B infection constitutes an important cause of morbidity and mortality worldwide. In Brazil, however, the current epidemiological situation is not clear. Considering the importance of establishing this prevalence, the aim of this study was to determine the prevalence of HBV markers in voluntary adolescents, junior high (secondary school) students, in the City of Itajaí, State of Santa Catarina, Brazil. Methods: A seroepidemiological, transverse study was conducted with 353 randomly chosen adolescents from elementary school in 2008. Blood samples were analyzed for HBsAg, anti-HBc and anti-HBs. All analyses were conducted by automated microparticle enzyme immunosorbent assay (Abbott®, AxSYM system, Deerfield, IL, USA), according to the manufacturer's instructions. Results: The prevalence of HBsAg was 0.6% (CI 95% 0.1 -2.0), that of anti-HBc was 1.1% (CI 95% 0.3 -2.9) and that of detectable anti-HBs was 83.6% (CI 95% 79.3 -87.3). Hepatitis B vaccination coverage was 97.5% (CI 95% 95.2 -98.8). Conclusions: These results demonstrate the success of the vaccination program against hepatitis B in the region studied and indicate that prevention strategies must be maintained and, if possible, expanded to contribute to the establishment of positive prevalence rates in all age groups.

show abstract

“…The authors believe that the vaccine booster is not necessary in these children, since the HBsAg positivity rate in this population did not rise in later years. 58 Zanetti et al, 59 in Italy, analyzed immunity duration and the eventual need for a booster dose in 1,212 children and 446 air force recruits, after 10 years of implementing vaccination in nursing infants and adolescents in that country. They concluded that a strong immunologic memory persists for over 10 years after a primary course of immunization, and booster doses of the vaccine are unnecessary.…”

Section: Hepatitis B Vaccinementioning

confidence: 99%

Prevenção das hepatites virais através de imunização

Ferreira¹,

Silveira²

2006

J. Pediatr. (Rio J.)

View full text Add to dashboard Cite

Objective: To present an updated review and criticism of viral hepatitis A and B prevention by immunization. Summary of the findings: Viral hepatitis prevention is an enormous challenge to the public health systems of countries and the medical and scientific communities. Hepatitis viruses produce important morbimortality in the world, causing acute and chronic hepatic disease. There are highly efficient vaccines available on the market to prevent new infections by the A and B viruses. However, A and B viruses continue to be among the most commonly notified diseases preventable by vaccines. In this article, we discuss the vaccines used to prevent these infections, with the aim of expanding knowledge and the practice of prevention of these infectious diseases.Conclusions: Although the vaccines against A and B hepatitis are recommended for various risk groups, estimated vaccine coverage is still modest and many vaccination opportunities are lost. In order to reduce the incidence of A and B hepatitis, which are preventable by vaccines, it is necessary for physicians to encourage their patients to be vaccinated.

show abstract

Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study

Cited by 323 publications

References 27 publications

Seroprevalence of hepatitis B and hepatitis C markers in adolescents in Southern Brazil

Seroprevalence of hepatitis B and hepatitis C markers in adolescents in Southern Brazil

Hepatitis B marker seroprevalence and vaccination coverage in adolescents in the City of Itajaí, State of Santa Catarina, Southern Brazil, in 2008

Prevenção das hepatites virais através de imunização

Contact Info

Product

Resources

About